Table 1 Basic characteristics between patients receiving UFT or S-1 as adjuvant chemotherapy

Sex (male)

56

(65.1)

25

(67.6)

31

(63.3)

0.85

Age (years old)

57.5

± 12.2

59.1

± 13.9

56.3

± 10.7

0.31

Operative method

0.10

 Distal gastrectomy

65

(75.6)

26

(70.3)

39

(79.6)

 Total gastrectomy

18

(20.9)

11

(29.7)

7

(14.3)

 Proximal gastrectomy

3

(3.5)

0

(0)

3

(6.1)

Site

0.33

 Antrum and low body

61

(70.9)

26

(70.3)

35

(71.4)

 Middle and high body

18

(20.9)

9

(24.3)

9

(18.4)

 Whole stomach

1

(1.2)

1

(2.7)

0

(0)

 Remnant

6

(7.0)

1

(2.7)

5

(10.2)

Size (cm)

4.4

± 2.0

4.3

± 2.0

4.6

± 2.1

0.49

Bormann type

0.047*

 I or II

21

(24.4)

5

(13.5)

16

(32.7)

 III or IV

65

(75.6)

32

(86.5)

33

(67.3)

Lauren classification

0.49

 Intestinal type

31

(36.0)

13

(35.1)

18

(36.7)

 Diffuse type

39

(45.3)

19

(51.4)

20

(40.8)

 Mixed type

16

(18.6)

5

(13.5)

11

(22.4)

Cell differentiation

0.54

 Well-differentiated

7

(8.2)

4

(11.1)

3

(6.1)

 Moderately differentiated

23

(27.1)

11

(30.6)

12

(24.5)

 Poorly- or un-differentiated

55

(64.7)

21

(58.3)

34

(69.4)

LN metastasis (number)

4.5

± 5.7

5.2

± 7.8

3.9

± 3.3

0.35

LN harvested (number)

34.9

± 18.6

33.9

± 19.3

35.6

± 18.2

0.67

Lymphovascular invasion

56

(65.1)

25

(67.6)

31

(63.3)

0.85

Perineural invasion

57

(66.3)

25

(67.6)

32

(65.3)

0.99

T stage (AJCC 8^th)

<0.001*

 1

0

(0)

0

(0)

0

(0)

 2

19

(21.8)

8

(21.6)

11

(22.4)

 3

42

(48.3)

8

(21.6)

33

(67.3)

 4

26

(29.9)

21

(56.8)

5

(10.2)

N stage (AJCC 8^th)

0.48

 0

2

(2.3)

0

(0)

2

(4.1)

 1

33

(38.4)

15

(40.5)

18

(36.7)

 2

36

(41.9)

14

(37.8)

22

(44.9)

 3

15

(17.4)

8

(21.6)

7

(14.3)

Pathological stage (AJCC 8^th)

0.23

 II

33

(38.4)

11

(29.7)

22

(44.9)

 III

53

(61.6)

26

(70.3)

27

(55.1)

Follow-up (months)

52.6

± 31.2

65.9

± 36.9

43.3

± 22.6

0.003*